RxDoctor Payments DataLook up a doctor →

Bryan Hay, MD

Pulmonary Disease · Nashville, TNNPI 1962778167

Payments from drug & device makers

$126,335in general payments, 2019–2025

Across 822 payments — averaging $153.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$112K
  • AstraZeneca$2K
  • Boehringer Ingelheim$2K
  • GSK$2K
  • Insmed, Inc.$997
  • Grifols USA, LLC$884
  • plus $6K from 36 others

What the payments were for

  • Speaking & faculty fees$10,0008%
  • Travel & lodging$8,7997%
  • Food & beverage$19,64316%
  • Education$87,89370%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$126,335 in reported general payments places this provider in the 90th percentile of 339 pulmonary disease providers in Tennessee.

See all pulmonary disease providers in Tennessee

Medicare billing

Part B allowed, 2024
$170,193
Medicare patients
466
Services billed
1,992

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate29$367,854
Trelegy ElliptaFluticasone/Umeclidin/Vilanter427$346,898
Dupixent PenDupilumab24$92,906
Breztri AerosphereBudesonide/Glycopyr/Formoterol128$92,775
NucalaMepolizumab22$82,770
Dupixent SyringeDupilumab14$78,881
FasenraBenralizumab11$61,467
XolairOmalizumab24$48,917
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr87$46,962
Breo ElliptaFluticasone/Vilanterol53$28,082
Stiolto RespimatTiotropium Br/Olodaterol Hcl25$15,458
EliquisApixaban14$15,208
SymbicortBudesonide/Formoterol Fumarate44$14,382
Advair HfaFluticasone Propion/Salmeterol21$9,862
Albuterol Sulfate HfaAlbuterol Sulfate281$7,779

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta$1,919$504,712589 claims
Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat$1,944$388,84865 claims
AstraZenecaBreztri Aerosphere, Fasenra, Symbicort$2,197$168,624183 claims
PfizerEliquis$247$15,20814 claims
Johnson & JohnsonXarelto$114$5,89311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 339 pulmonary disease providers in Tennessee.

Other pulmonary disease in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →